BioCryst Pharmaceuticals, Inc. is a U.S. biotechnology company headquartered in Durham, North Carolina, specializing in the development of oral small-molecule therapies and injectable proteins for rare and serious diseases.
ORLADEYO (berotralstat) is the cornerstone of BioCryst's recent commercial success. It is an oral preventive treatment, taken once daily, for attacks of Hereditary Angioedema (HAE). It was approved by the FDA in December 2020 and has been launched in multiple global markets.
The ORLADEYO market expansion continues with the recent FDA approval of oral pellets for pediatric HAE patients aged 2 to under 12 years. This approval extends the drug's availability to approximately 500 diagnosed pediatric patients, of which around 40% are currently on treatment, further driving demand and bringing the company closer to its peak sales goal of $1 billion.
ORLADEYO net revenue in the third quarter of 2025 reached $159.1 million, representing an impressive 37% year-over-year growth. Thanks to this performance, BioCryst raised its ORLADEYO revenue forecast for fiscal year 2025 to a range of $590 million to $600 million.
BioCryst's financial results for the third quarter of 2025 show strong momentum, with significant revenue growth from ORLADEYO and expectations of profitability for the full year, ahead of schedule.
Expansion
BioCryst Pharmaceuticals has signed a definitive agreement to acquire Astria Therapeutics, a biotechnology company focused on transformative therapies for patients with allergic and immunological diseases.
Navenibart (STAR-0215)—a long-acting injectable preventive treatment designed for HAE attacks—is the primary asset driving the acquisition's value for BioCryst.
Although Navenibart is the main driver of the acquisition, STAR-0310—a monoclonal antibody OX40 antagonist designed with the potential to be a first-choice treatment for Atopic Dermatitis (AD)—introduces significant diversification value.
The transaction is expected to close in the first quarter of 2026.
BioCryst maintains a research and development focus beyond HAE, centered on the development of its next-generation oral Factor D inhibitor, BCX10013. Other assets in the portfolio include BCX17725, for which an Investigational New Drug (IND) application was submitted in the U.S. for Netherton syndrome.
Key Points
• BioCryst has created an effective monopoly in the two preferred dosing modalities for HAE prophylaxis: daily oral (ORLADEYO) and ultra-low-frequency injectable (Navenibart).
• The company has demonstrated strong financial management, securing growth capital through the monetization of peripheral assets and achieving profitability ahead of schedule.
• STAR-0310 represents a high-potential differentiation asset that, if successful, could unlock significant value in a much larger market than HAE.
Technical Analysis
The company's stock price action supports a likely medium- and long-term upside. The presence of large volumes and the rounded shape of the accumulation reveal strong institutional investor presence.
ORLADEYO (berotralstat) is the cornerstone of BioCryst's recent commercial success. It is an oral preventive treatment, taken once daily, for attacks of Hereditary Angioedema (HAE). It was approved by the FDA in December 2020 and has been launched in multiple global markets.
The ORLADEYO market expansion continues with the recent FDA approval of oral pellets for pediatric HAE patients aged 2 to under 12 years. This approval extends the drug's availability to approximately 500 diagnosed pediatric patients, of which around 40% are currently on treatment, further driving demand and bringing the company closer to its peak sales goal of $1 billion.
ORLADEYO net revenue in the third quarter of 2025 reached $159.1 million, representing an impressive 37% year-over-year growth. Thanks to this performance, BioCryst raised its ORLADEYO revenue forecast for fiscal year 2025 to a range of $590 million to $600 million.
BioCryst's financial results for the third quarter of 2025 show strong momentum, with significant revenue growth from ORLADEYO and expectations of profitability for the full year, ahead of schedule.
Expansion
BioCryst Pharmaceuticals has signed a definitive agreement to acquire Astria Therapeutics, a biotechnology company focused on transformative therapies for patients with allergic and immunological diseases.
Navenibart (STAR-0215)—a long-acting injectable preventive treatment designed for HAE attacks—is the primary asset driving the acquisition's value for BioCryst.
Although Navenibart is the main driver of the acquisition, STAR-0310—a monoclonal antibody OX40 antagonist designed with the potential to be a first-choice treatment for Atopic Dermatitis (AD)—introduces significant diversification value.
The transaction is expected to close in the first quarter of 2026.
BioCryst maintains a research and development focus beyond HAE, centered on the development of its next-generation oral Factor D inhibitor, BCX10013. Other assets in the portfolio include BCX17725, for which an Investigational New Drug (IND) application was submitted in the U.S. for Netherton syndrome.
Key Points
• BioCryst has created an effective monopoly in the two preferred dosing modalities for HAE prophylaxis: daily oral (ORLADEYO) and ultra-low-frequency injectable (Navenibart).
• The company has demonstrated strong financial management, securing growth capital through the monetization of peripheral assets and achieving profitability ahead of schedule.
• STAR-0310 represents a high-potential differentiation asset that, if successful, could unlock significant value in a much larger market than HAE.
Technical Analysis
The company's stock price action supports a likely medium- and long-term upside. The presence of large volumes and the rounded shape of the accumulation reveal strong institutional investor presence.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.